Table of Contents Author Guidelines Submit a Manuscript
Research Letters in Biochemistry
Volume 2009, Article ID 151424, 4 pages
Research Letter

Inhibition of Candida albicans by Fluvastatin Is Dependent on pH

Department of Biochemistry and Nutrition, Des Moines University, 3200 Grand Avenue, Des Moines, IA 50312, USA

Received 1 June 2009; Accepted 13 July 2009

Academic Editor: Edna S. Kaneshiro

Copyright © 2009 Martin Schmidt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. G. Macreadie, G. Johnson, T. Schlosser, and P. I. Macreadie, “Growth inhibition of Candida species and Aspergillus fumigatus by statins,” FEMS Microbiology Letters, vol. 262, no. 1, pp. 9–13, 2006. View at Publisher · View at Google Scholar
  2. J. D. Nash, D. S. Burgess, and R. L. Talbert, “Effect of fluvastatin and pravastatin, HMG-coA reductase inhibitors, on fluconazole activity against Candida albicans,” Journal of Medical Microbiology, vol. 51, no. 2, pp. 105–109, 2002. View at Google Scholar
  3. N.-X. Chin, I. Weitzman, and P. Della-Latta, “In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and cryptococcus neoformans,” Antimicrobial Agents and Chemotherapy, vol. 41, no. 4, pp. 850–852, 1997. View at Google Scholar
  4. A. Lindahl, S. Frid, A. L. Ungell, and H. Lennernas, “No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat,” AAPS PharmSci, vol. 2, no. 3, p. E26, 2000. View at Publisher · View at Google Scholar
  5. F. De Seta, M. Schmidt, B. Vu, M. Essmann, and B. Larsen, “Antifungal mechanisms supporting boric acid therapy of Candida vaginitis,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 2, pp. 325–336, 2009. View at Publisher · View at Google Scholar
  6. D. Burke, D. Dawson, and T. Stearns, Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, USA, 2000.
  7. P. A. Wayne, “National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition,” NNCLS Document M27-A3, Clinical and Laboratory Standards Institute, 2008.
  8. B. Larsen, S. Anderson, A. Brockman, M. Essmann, and M. Schmidt, “Key physiological differences in Candida albicans CDRI induction by steroid hormones and antifungal drugs,” Yeast, vol. 23, no. 11, pp. 795–802, 2006. View at Publisher · View at Google Scholar
  9. D. Carling, P. R. Clarke, V. A. Zammit, and D. G. Hardie, “Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities,” European Journal of Biochemistry, vol. 186, no. 1-2, pp. 129–136, 1989. View at Publisher · View at Google Scholar
  10. S. Znaidi, S. Weber, O. Z. Al-Abdin et al., “Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance,” Eukaryotic Cell, vol. 7, no. 5, pp. 836–847, 2008. View at Publisher · View at Google Scholar
  11. F. C. Odds, A. J. P. Brown, and N. A. R. Gow, “Antifungal agents: mechanisms of action,” Trends in Microbiology, vol. 11, no. 6, pp. 272–279, 2003. View at Publisher · View at Google Scholar
  12. R. L. White, D. S. Burgess, M. Manduru, and J. A. Bosso, “Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 8, pp. 1914–1918, 1996. View at Google Scholar
  13. J. L. Song, C. N. Lyons, S. Holleman, B. G. Oliver, and T. C. White, “Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans,” Medical Mycology, vol. 41, no. 5, pp. 417–425, 2003. View at Publisher · View at Google Scholar
  14. R. Siekmeier, P. Lattke, C. Mix, J.-W. Park, and W. Jaross, “Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 6, no. 2, pp. 137–145, 2001. View at Google Scholar